ONCOMED PHARMACEUTICALS INC's ticker is OMED and the CUSIP is 68234X102. A total of 86 filers reported holding ONCOMED PHARMACEUTICALS INC in Q2 2016. The put-call ratio across all filers is 1.20 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $5,000 | -16.7% | 2,019 | 0.0% | 0.00% | -33.3% |
| Q1 2018 | $6,000 | -25.0% | 2,019 | 0.0% | 0.00% | -40.0% |
| Q4 2017 | $8,000 | -76.5% | 2,019 | -73.1% | 0.01% | -77.3% |
| Q3 2017 | $34,000 | +36.0% | 7,519 | 0.0% | 0.02% | +29.4% |
| Q2 2017 | $25,000 | -63.8% | 7,519 | 0.0% | 0.02% | -66.0% |
| Q1 2017 | $69,000 | +19.0% | 7,519 | 0.0% | 0.05% | -3.8% |
| Q4 2016 | $58,000 | -31.8% | 7,519 | 0.0% | 0.05% | -42.9% |
| Q3 2016 | $85,000 | -7.6% | 7,519 | 0.0% | 0.09% | -10.8% |
| Q2 2016 | $92,000 | +21.1% | 7,519 | 0.0% | 0.10% | +47.8% |
| Q1 2016 | $76,000 | -55.0% | 7,519 | 0.0% | 0.07% | -48.9% |
| Q4 2015 | $169,000 | +36.3% | 7,519 | 0.0% | 0.14% | -12.3% |
| Q3 2015 | $124,000 | -26.6% | 7,519 | 0.0% | 0.15% | -16.3% |
| Q2 2015 | $169,000 | -12.9% | 7,519 | 0.0% | 0.18% | -6.6% |
| Q1 2015 | $194,000 | +18.3% | 7,519 | 0.0% | 0.20% | +13.2% |
| Q4 2014 | $164,000 | – | 7,519 | – | 0.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 4,108,815 | $4,273,000 | 0.48% |
| Birchview Capital, LP | 372,557 | $387,000 | 0.24% |
| Perceptive Advisors | 1,719,111 | $1,787,000 | 0.05% |
| Fondren Management LP | 25,136 | $26,000 | 0.02% |
| Cannell & Co. | 281,983 | $293,000 | 0.01% |
| APPLETON PARTNERS INC/MA | 66,206 | $69,000 | 0.01% |
| Quinn Opportunity Partners LLC | 66,162 | $69,000 | 0.01% |
| NJ State Employees Deferred Compensation Plan | 38,000 | $40,000 | 0.01% |
| Candriam S.C.A. | 380,000 | $395,000 | 0.01% |
| PRIMECAP MANAGEMENT CO/CA/ | 5,451,400 | $5,669,000 | 0.00% |